The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Open accessAbstract
PURPOSE: To evaluate the efficacy and ocular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepinephrine transporter inhibitor, in patients with open-angle glaucoma and ocular hypertension. DESIGN: Double-masked, randomized noninferiority clinical trials: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). METHODS: After a washout of all pre-study ocular hypotensive medications, eligible patients were randomized to receive netarsudil 0.02% once daily (q.d.), timolol 0.5% twice a day (b.i.d.), and (ROCKET-2 only) netarsudil 0.02% b.i.d. Data through 3 months from both studies are provided in this report. RESULTS: Enrolled into the 2 studies were 1167 patients. Treatment with netarsudil q.d. produced clinically and statistically significant reductions from baseline intraocular pressure (P < .001), and was noninferior to timolol in the per-protocol population with maximum baseline IOP < 25 mm Hg in both studies (ROCKET-2, primary outcome measure and population, ROCKET-1, post hoc outcome measure). Netarsudil b.i.d. was also noninferior to timolol (ROCKET-2). The most frequent adverse event was conjunctival hyperemia, the incidence of which ranged from 50% (126/251, ROCKET-2) to 53% (108/203, ROCKET-1) for netarsudil q.d., 59% (149/253, ROCKET-2) for netarsudil b.i.d., and 8% (17/208, ROCKET-1) to 11% (27/251, ROCKET-2) for timolol (P < .0001 for netarsudil vs timolol). CONCLUSIONS: In 2 large, randomized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effective and well tolerated for the treatment of patients with ocular hypertension and open-angle glaucoma. The novel pharmacology and aqueous humor dynamic effects of this molecule suggest it may be a useful addition to the armamentarium of ocular hypotensive medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kass, M. A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.701 · Cited by 3,705
Heijl, A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1268 · Cited by 3,320
(2000) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(00)00538-9 · Cited by 2,780
Lichter, P. (2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00873-9 · Cited by 1,178
Terminology and guidelines for glaucoma
Molina-Castañer, S. (2009) · Hispana · Cited by 665
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
Garway-Heath, D. F., Crabb, D. P., Bunce, C., Lascaratos, G., Amalfitano, F., Anand, N., Azuara-Blanco, A., Bourne, R. R., Broadway, D. C., Cunliffe, I. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62111-5 · Cited by 660
Definition of glaucoma: clinical and experimental concepts
Casson, R. J., Chidlow, G., Wood, J. P., Crowston, J. G., & Goldberg, I. (2012) · Clinical & Experimental Ophthalmology · doi:10.1111/j.1442-9071.2012.02773.x · Cited by 510
Adherence in Glaucoma: Objective Measurements of Once-Daily and Adjunctive Medication Use
Robin, A. L., Novack, G. D., Covert, D. W., Crockett, R. S., & Marcic, T. S. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.06.012 · Cited by 328
Self-citationMedical Management of Glaucoma
Alward, W. L. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810293391808 · Cited by 252
An Objective Evaluation of Eyedrop Instillation in Patients With Glaucoma
Stone, J. L. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.96 · Cited by 230
Cited by
Jayaram, H., Kolko, M., Friedman, D. S., & Gazzard, G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01289-8 · Cited by 592
Primary Open-Angle Glaucoma Preferred Practice Pattern®
Gedde, S. J., Vinod, K., Wright, M. M., Muir, K. W., Lind, J. T., Chen, P. P., Li, T., & Mansberger, S. L. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.10.022 · Cited by 474
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Tanna, A. P., & Johnson, M. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.04.040 · Cited by 257
Li, H., Henty-Ridilla, J. L., Bernstein, A. M., Ganapathy, P. S., & Herberg, S. (2022) · Current Eye Research · doi:10.1080/02713683.2022.2071943 · Cited by 29
Metadata
- Authors
- Serle, J. B., Katz, L. J., McLaurin, E., Heah, T., Ramirez-Davis, N., Usner, D. W., Novack, G. D., & Kopczynski, C. C.
- Venue
- American Journal of Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 186
- Pages
- 116-127
- ISSN
- 0002-9394 (ISSN-L)
- OpenAlex
- W2773591092
- Cited by
- 269
- References
- 23
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). https://app.cochat.ai/papers/10.1016/j.ajo.2017.11.019
- The paper
- Serle, J. B., Katz, L. J., McLaurin, E., Heah, T., Ramirez-Davis, N., Usner, D. W., Novack, G. D., & Kopczynski, C. C. (2018). Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2017.11.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.